Extendicare
Market Cap
CA$724.6m
Last Updated
2021/05/16 00:17 UTC
Data Sources
Company Financials +
Executive Summary
Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. More Details
Snowflake Analysis
Proven track record average dividend payer.
Share Price & News
How has Extendicare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EXE is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: EXE's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
3.2%
EXE
-3.9%
CA Healthcare
-0.7%
CA Market
1 Year Return
41.4%
EXE
32.5%
CA Healthcare
39.3%
CA Market
Return vs Industry: EXE exceeded the Canadian Healthcare industry which returned 33.6% over the past year.
Return vs Market: EXE exceeded the Canadian Market which returned 39.2% over the past year.
Shareholder returns
| EXE | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.2% | -3.9% | -0.7% |
| 30 Day | 3.3% | -7.7% | 1.0% |
| 90 Day | 26.0% | -8.7% | 6.1% |
| 1 Year | 53.0%41.4% | 35.1%32.5% | 43.8%39.3% |
| 3 Year | 29.9%5.9% | 82.5%60.7% | 28.6%16.4% |
| 5 Year | 28.3%-5.7% | 12.6%-14.1% | 58.6%34.7% |
Long-Term Price Volatility Vs. Market
How volatile is Extendicare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Extendicare (TSE:EXE) Shareholders Booked A 36% Gain In The Last Year3 weeks ago | Simply Wall St
Read This Before Considering Extendicare Inc. (TSE:EXE) For Its Upcoming CA$0.04 Dividend1 month ago | Simply Wall St
Extendicare (TSE:EXE) Has A Pretty Healthy Balance SheetValuation
Is Extendicare undervalued compared to its fair value and its price relative to the market?
14.96x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: EXE (CA$8.09) is trading above our estimate of fair value (CA$5.59)
Significantly Below Fair Value: EXE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: EXE is good value based on its PE Ratio (15x) compared to the Canadian Healthcare industry average (18.1x).
PE vs Market: EXE's PE Ratio (15x) is in line with the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EXE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EXE is overvalued based on its PB Ratio (5.8x) compared to the CA Healthcare industry average (4.2x).
Future Growth
How is Extendicare forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
3.2%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if EXE's forecast earnings growth is above the savings rate (1.5%).
Earnings vs Market: Insufficient data to determine if EXE's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EXE's revenue (3.2% per year) is forecast to grow slower than the Canadian market (6.3% per year).
High Growth Revenue: EXE's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EXE's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Extendicare performed over the past 5 years?
-4.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXE has high quality earnings.
Growing Profit Margin: EXE's current net profit margins (4.1%) are higher than last year (1.6%).
Past Earnings Growth Analysis
Earnings Trend: EXE's earnings have declined by 4.6% per year over the past 5 years.
Accelerating Growth: EXE's earnings growth over the past year (178%) exceeds its 5-year average (-4.6% per year).
Earnings vs Industry: EXE earnings growth over the past year (178%) exceeded the Healthcare industry 34.1%.
Return on Equity
High ROE: Whilst EXE's Return on Equity (38.67%) is high, this metric is skewed due to their high level of debt.
Financial Health
How is Extendicare's financial position?
Financial Position Analysis
Short Term Liabilities: EXE's short term assets (CA$268.9M) do not cover its short term liabilities (CA$277.9M).
Long Term Liabilities: EXE's short term assets (CA$268.9M) do not cover its long term liabilities (CA$527.4M).
Debt to Equity History and Analysis
Debt Level: EXE's debt to equity ratio (374.2%) is considered high.
Reducing Debt: EXE's debt to equity ratio has increased from 217.3% to 374.2% over the past 5 years.
Debt Coverage: EXE's debt is not well covered by operating cash flow (18.6%).
Interest Coverage: EXE's interest payments on its debt are well covered by EBIT (3.2x coverage).
Balance Sheet
Dividend
What is Extendicare current dividend yield, its reliability and sustainability?
5.93%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: EXE's dividend (5.93%) is higher than the bottom 25% of dividend payers in the Canadian market (1.53%).
High Dividend: EXE's dividend (5.93%) is in the top 25% of dividend payers in the Canadian market (4.53%)
Stability and Growth of Payments
Stable Dividend: EXE's dividends per share have been stable in the past 10 years.
Growing Dividend: EXE's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (88.7%), EXE's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.4yrs
Average management tenure
CEO
Michael Guerriere (56 yo)
2.58yrs
Tenure
CA$1,713,124
Compensation
Dr. Michael R. Guerriere, MD, MBA, has been the Chief Executive Officer and President at Extendicare Inc. since joined in October 22, 2018. Dr. Guerriere serves as Chairman and Chief Executive Officer of E...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD1.42M) is above average for companies of similar size in the Canadian market ($USD793.46K).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: EXE's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
Experienced Board: EXE's board of directors are considered experienced (4.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EXE insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Extendicare Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Extendicare Inc.
- Ticker: EXE
- Exchange: TSX
- Founded: 1968
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: CA$724.561m
- Shares outstanding: 89.56m
- Website: https://www.extendicare.com
Number of Employees
Location
- Extendicare Inc.
- 3000 Steeles Avenue East
- Suite 103
- Markham
- Ontario
- L3R 4T9
- Canada
Listings
Biography
Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; retirement living services; and home health care services, su...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/16 00:17 |
| End of Day Share Price | 2021/05/14 00:00 |
| Earnings | 2021/03/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.